Page 34 - Nsclc News Today

Conclusions from the first interim analysis of overall survival in the IMpower010 trial of adjuvant atezolizumab for non–small cell lung cancer has been met with some pushback.

Expert oncologists present the case of a 45-year-old woman with synaptophysin-positive, extensive-stage small-cell lung cancer with a Ki-67 score of 90%, who is treated with carboplatin, etoposide, and atezolizumab in the first-line setting, and provide their initial impressions.

Expert panelists discuss the characterization of patients with unresectable, early-stage NSCLC and what their standard treatment approach is for this patient population.

Ben Levy, MD, reviews the 5-year update and clinical implications of the PACIFIC study which evaluated consolidation immunotherapy in unresectable early-stage NSCLC.

Luis E. Raez, MD, discusses how findings from the phase 2 NADIM II trial inform the neoadjuvant treatment paradigm in non–small cell lung cancer.

First-line atezolizumab monotherapy was associated with improved overall survival and maintenance of quality of life compared with single-agent chemotherapy for patients with advanced NSCLC.

The panelists explore the groundbreaking ADAURA trial, covering its study design, efficacy and safety results, and the current clinical implications.

Amivantamab-vmjw (Rybrevant) showed efficacy in a phase 3 trial of patients with newly diagnosed advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR mutations.

Joseph Christopher Murray, MD, discusses the role of prognostic markers in non–small cell lung cancer and how data from the EMPOWER trials will guide future directions in the space.

Jarushka Naidoo, MBBCh, discussed the clinical significance of datasets from several phase 3 trials presented at the 2023 ASCO Annual Meeting, including ADAURA, KEYNOTE-617, CheckMate 816, and CheckMate 9LA trials.